Zhejiang Agriculture & Forestry University, Hangzhou 311300, China.
Zhejiang Key Laboratory of Diagnosis & Treatment Technology on Thoracic Oncology (lung and esophagus), Zhejiang Cancer Hospital, Hangzhou 310022, China.
Biosens Bioelectron. 2017 Nov 15;97:184-195. doi: 10.1016/j.bios.2017.05.050. Epub 2017 May 31.
Small cell lung cancer (SCLC) is a smoking-related cancer disease. Despite improvement in clinical survival, SCLC outcome remains extremely poor. Cisplatin (DDP) is the first-line chemotherapy drug for SCLC, but the choice of second-line chemotherapy drugs is not clear. In this paper, a SCLC cell-based sensor was proposed, and its applications in chemotherapy effects rapid evaluation for anticancer drugs were investigated. SCLC cell lines lung adenocarcinoma cell (LTEP-P) and DDP-resistant lung adenocarcinoma cell (LTEP-P/DDP-1.0) are cultured on carbon screen-printed electrode (CSPE) to fabricate integrated cell-based sensor. Several chemotherapy anticancer drugs, including cisplatin, ifosmamide, gemcitabine, paclitaxel, docetaxel, vinorelbine, etoposide, camptothecin, and topotecan, are selected as experimental chemicals. 3-(4,5-Dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) tests are conducted to evaluate chemotherapy drug effects on LTEP-P and LTEP-P/DDP-1.0 cell lines. Electrical cell-substrate impedance sensing (ECIS) responses to anti-tumor chemicals are measured and processed by double-layered cascaded stochastic resonance (DCSR). Cisplatin solutions in different concentrations measurement results demonstrate that LTEP-P cell-based sensor presents quantitative analysis abilities for cisplatin and topotecan. Cisplatin and its mixtures can also be discriminated. Results demonstrate that LTEP-P cell-based sensor sensitively evaluates chemotherapy drugs' apoptosis function to SCLC cells. LTEP-P/DDP-1.0 cell-based sensor responses demonstrate that gemcitabine, vinorelbine, and camptothecin are ideal second-line drugs for clinical post-cisplatin therapy than other drugs according to MTT test results. This work provides a novel way for SCLC second-line clinical chemotherapy drug screening.
小细胞肺癌（SCLC）是一种与吸烟有关的癌症疾病。尽管临床生存率有所提高，但 SCLC 的预后仍然非常差。顺铂（DDP）是 SCLC 的一线化疗药物，但二线化疗药物的选择尚不清楚。本文提出了一种基于 SCLC 细胞的传感器，并研究了其在评估抗癌药物化疗效果方面的应用。将肺腺癌细胞（LTEP-P）和 DDP 耐药肺腺癌细胞（LTEP-P/DDP-1.0）培养在碳丝网印刷电极（CSPE）上，以制备集成的基于细胞的传感器。选择几种化疗抗癌药物，包括顺铂、异环磷酰胺、吉西他滨、紫杉醇、多西他赛、长春瑞滨、依托泊苷、喜树碱和拓扑替康，作为实验化学品。MTT 试验用于评估 LTEP-P 和 LTEP-P/DDP-1.0 细胞系中化疗药物的作用。通过双层级联随机共振（DCSR）测量和处理针对抗肿瘤化学品的电细胞-基底阻抗传感（ECIS）响应。不同浓度顺铂溶液的测量结果表明，LTEP-P 细胞传感器具有对顺铂和拓扑替康进行定量分析的能力。还可以区分顺铂及其混合物。结果表明，LTEP-P 细胞传感器能够灵敏地评估化疗药物对 SCLC 细胞的凋亡作用。根据 MTT 试验结果，LTEP-P/DDP-1.0 细胞传感器的响应表明，与其他药物相比，吉西他滨、长春瑞滨和喜树碱是临床顺铂治疗后理想的二线药物。这项工作为 SCLC 二线临床化疗药物筛选提供了一种新方法。
